Costs of PSMA Therapy

What Are the Costs of PSMA Therapy Composed Of?

The costs of PSMA therapy arise from several medical and organizational components. It is a specialized nuclear medicine procedure that requires both a highly specific radiopharmaceutical and the appropriate infrastructure.

The main cost factors include:

• The radiopharmaceutical (Lutetium-177 PSMA) - production, quality assurance, transport, and regulated disposal of radioactive waste
• Medical services - consultation, evaluation of the medical indication, administration of therapy, and follow-up assessments
• Nuclear medicine infrastructure - specialized treatment rooms, radiation protection measures, and legally required safety protocols
• Laboratory monitoring and follow-up - regular blood tests between treatment cycles
• Associated diagnostics - particularly PSMA PET/CT imaging, which is usually a prerequisite for therapy

Since treatment is typically carried out over multiple cycles, total costs may consist of several individual treatment sessions.

The exact amount depends on the individual treatment plan, the number of cycles, and insurance-related conditions. For this reason, financial aspects are clarified transparently before the start of therapy.

Cost Coverage by Statutory Health Insurance (Austria)

In Austria, cost coverage for PSMA therapy is generally not granted automatically, but is assessed on a case-by-case basis by the respective health insurance provider.

A key requirement is a medically justified indication for PSMA therapy. The evaluation includes whether:

• Advanced or metastatic prostate cancer is present
• Established therapies are no longer sufficiently effective
• Sufficient PSMA expression has been demonstrated by PSMA PET/CT
• The therapy is medically justified and in line with clinical guidelines

Based on this information, an application for cost coverage can be submitted. The final decision is made by the respective health insurance provider.

Processing times may vary. In some cases, additional medical documentation may be requested. Clear and transparent medical documentation facilitates the review process.

Cost coverage may be granted on an individual basis if the requirements are met. However, blanket approval without prior assessment is not common.

Private Health Insurance

For privately insured patients, coverage of the costs for PSMA therapy depends on the specific insurance plan and the contractually agreed benefits.

In many cases, cost coverage is possible if:

• A medically justified indication for PSMA therapy (link to Indication) is present
• The treatment is in line with clinical guidelines
• The necessary diagnostic requirements—particularly PSMA PET/CT—are fulfilled

However, insurance conditions vary depending on the provider and plan. Therefore, it is often necessary to submit a written cost request or cost estimate before starting therapy.

Early coordination with the private health insurance provider can help avoid potential queries or delays. The following documents are usually required:

• Medical report
• Justification of the therapy indication
• Cost estimate of the planned treatment

The final decision on cost coverage is made by the respective insurance company based on the submitted documentation.

Self-Paying and International Patients

For patients without coverage through statutory or private health insurance, PSMA therapy can generally be accessed as a self-pay treatment.

In such cases, a transparent written cost estimate is provided before the start of therapy. This includes:

• The radiopharmaceutical (Lutetium-177 PSMA)
• Medical services and administration of the therapy
• Legally required radiation protection measures
• Accompanying laboratory tests and follow-up monitoring
• If necessary, PSMA PET/CT imaging, if not already available

Since the therapy is usually carried out in multiple cycles, the cost structure is planned accordingly and explained clearly in advance.

For international patients, additional organizational coordination may be required regarding appointment scheduling, transfer of medical documents, and payment arrangements. These aspects are also clarified prior to the start of treatment.

Regardless of the type of insurance, a medical evaluation of the indication for PSMA therapy is always conducted before any cost-related decisions are made.

Why Is the Evaluation of Indication Crucial for Cost Considerations?

The decision for or against PSMA therapy should not be driven primarily by financial aspects, but must be based on a well-founded medical assessment.

A structured evaluation of the indication for PSMA therapy is therefore not only medically necessary, but also a prerequisite for appropriate cost clarification. Only once it has been established that the therapy is appropriate and guideline-based in the individual case can the question of cost coverage be assessed.

This medical evaluation includes:

• The stage of the disease in advanced or metastatic prostate cancer
• The previous course of treatment
• Current imaging, particularly PSMA PET/CT
• Overall health status

A clear indication provides transparency—both for the patient and for the insurance provider. It helps ensure that therapy is not initiated for financial or organizational reasons when there is no sufficient medical benefit to be expected.

PSMA PET/CT as Part of Cost Planning

PSMA PET/CT is generally a fundamental prerequisite for performing PSMA therapy. It serves not only for diagnosis, but also for assessing biological suitability.

Since the therapy is only meaningful if tumor cells express sufficient PSMA, PSMA PET/CT is an integral part of the medical decision-making process. Without this confirmation, targeted radioligand therapy is usually not indicated.

In terms of cost planning, this means:

• If a recent PSMA PET/CT is already available, it can be included in the evaluation of the indication
• If no suitable imaging has been performed, additional costs will arise for the examination
• The billing of diagnostic procedures may be handled separately, depending on the insurance situation

As with the therapy itself, cost coverage for PSMA PET/CT depends on the medical justification and the respective insurance provider.

Transparency at Theranosticum Vienna

The implementation of PSMA therapy requires not only medical expertise but also clear organizational planning. This includes a transparent presentation of the expected costs before the start of treatment.

At Theranosticum Vienna, cost clarification is carried out only after a structured medical evaluation of the indication for PSMA therapy. Based on this, an individualized cost estimate is prepared, clearly outlining all relevant components.

These include in particular:

• The radiopharmaceutical (Lutetium-177 PSMA)
• Medical services and administration of the therapy
• Legally required radiation protection measures
• Accompanying laboratory tests and follow-up monitoring
• If necessary, PSMA PET/CT imaging

Before the start of therapy, organizational procedures as well as the insurance situation are clarified. Our goal is to establish a medically and financially transparent basis for decision-making together with you.

Frequently Asked Questions About the Costs of PSMA Therapy

How much does PSMA therapy cost?

The costs of PSMA therapy consist of several components, including the radiopharmaceutical (Lutetium-177 PSMA), medical services, radiation protection measures, as well as laboratory tests and follow-up monitoring. The total cost depends on the number of treatment cycles and the individual treatment plan.

Is PSMA therapy covered by health insurance?

In Austria, cost coverage is generally not automatic. The decision is made on a case-by-case basis by the respective insurance provider. A prerequisite is a medically justified indication for PSMA therapy.

Is PSMA PET/CT included in the cost of the therapy?

PSMA PET/CT is usually a separate diagnostic service. Whether it has already been performed or is required as part of therapy planning affects the total cost.

Do I have to pay the costs upfront?

Whether advance payment is required depends on the specific insurance situation. For self-paying patients, a transparent cost estimate is provided before the start of therapy. For patients with statutory or private insurance, cost coverage is first assessed.

What happens if the insurance company declines coverage?

In the event of a rejection, it can be evaluated whether additional medical documentation can be submitted or a reassessment requested. The final decision rests with the respective insurance provider.

Are multiple treatment cycles billed separately?

Yes. Since PSMA therapy is carried out in multiple cycles, each individual treatment may be accounted for separately in the overall cost planning.